New compound may pave the way for anti-diabetic drugs with fewer side effects
Millions of people who struggle with blood glucose control as a result of having type 2 diabetes choose to buy Actos.
Millions of people who struggle with blood glucose control as a result of having type 2 diabetes choose to buy Actos. The metabolic disorder can negatively impact an individual's quality of life, which is why many studies continue to be conducted in order to develop more effective treatments.
Recently, research from the Scripps Research Institute and the Dana-Farber Cancer Institute unveiled a new compound that may lead to the development of anti-diabetic drugs. Lead author Patrick R. Griffin and his colleagues reported that such products may have minimal adverse side effects, a particularly important characteristic in light of the fact that many existing drugs can cause discomfort.
Griffin and his team revealed that a compound known as SR1664 may be the key to crafting these new and improved medications.
"In this study, we demonstrate that we have discovered novel compounds that work effectively through a unique mechanism of action on a well-validated clinical target for diabetes," said Griffin. "This unique mechanism of action appears to significantly limit side effects associated with marketed drugs."
An estimated 24 million children and adults struggle with diabetes in the U.S., according to statistics from the American Diabetes Association.
|
